DB15851ExperimentalVaccines
IMM-101 is a heat-inactivated immune-activating mycobacterial product. It has shown to be safe and well tolerated to complement conventional cancer therapy for patients with melanoma and pancreatic ductal adenocarcinoma [PMID:... Studies with IMM-101 showed the vaccine’s ability to stimulate cancer patients’ immune systems to help kill cancer cells.
Which companies are running trials of IMM101, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account